JERUSALEM, Oct. 22, 2019 /PRNewswire-PRWeb/ — RSIP Vision, a global leader in artificial intelligence (AI), computer vision, and image processing technology, has announced that they have collaborated with BioView (TASE:BIOV), a leading developer of cell imaging and analysis solutions, using artificial intelligence to classify chromosomes for highly accurate genetic testing results. Previously, cytologists performed manual chromosome classification that was timely and costly. The new AI solution drastically reduces time and the expense of genetic testing with a drastic improvement in results.

“Machine learning provides the unique capability to both segment and straighten out chromosomes so that the results that the patient receives are as accurate as possible,” says Ron Soferman, CEO of RSIP Vision. “When patients are undergoing genetic testing, it is often a sensitive time for them – they are testing for various conditions that could potentially affect their lives forever. Reducing the time for patients to receive the results of genetic testing is a step in making this process easier and smoother, providing patients with the correct answers, faster.”

This type of genetic testing, called karyotype classification is a common form of genetic testing that classifies and pairs the chromosomes to find any irregularities. Cytologists evaluate the size, shape, and number of chromosomes in the body’s cells as well abnormal locations and chromosome pieces, which can indicate irregular growth development or body functioning. The process of genetic testing has been greatly improved by machine learning since many data sets can easily be collected for the training phase. RSIP Vision, together with BioView’s team of algorithm and clinical experts, utilized a deep learning technique that is trained on very large datasets so that it could easily and accurately make precise data correlations and detect any abnormalities quickly.

“This is another breakthrough demonstrating our advanced capabilities in the field of pharma and biomedical imaging. With the use of AI, our team in conjunction with the BioView engineers, has been able to greatly improve the performance of classical tasks as well as deliver solutions for new and innovative projects,” said Alan Jerusalmi, PhD and VP of Pharma at RSIP Vision.

RSIP Vision recently announced other advanced solutions based on AI segmentation and machine learning including lung segmentation for precise interventional lung procedures and an AI module for knee replacement surgery.
Yuval Harari, Executive VP of BioView, says that he chose to work with RSIP Vision for several reasons: RSIP Vision’s expertise in AI, experience in medical devices, and the short time to market requirements. BioView has implemented this solution in its Duet Image and Analysis systems at several leading hospitals in the USA and Europe. “The feedback from the clinical operators has been very positive. The customers noted the increased throughput of the testing and the very accurate results they received as compared to other available solutions. We look forward to continue to work with RISP Vision on additional projects to help us provide the most efficient and accurate solutions on our cell imaging systems.”

About RSIP Vision
RSIP Vision is a global leader in artificial intelligence, computer vision, and image processing technology. The company draws on a depth of knowledge and experience to provide customized services, sophisticated algorithms, and deep learning technology to businesses of all kinds, most notably medical devices, pharmaceuticals, and autonomous driving.

RSIP Vision develops practical AI modules that ensure precision, reduce time to market, cut costs, and free the core R&D team staff for other endeavors, saving significant time and money and giving businesses a real edge over the competition. RSIP Vision partners with customers on scientific research and development projects using customized algorithms in fields including physics, computer science, mathematics, biomedicine, and neuroscience.
RSIP Vision is headquartered in Jerusalem, with U.S. offices in San Jose, CA, and Boston, MA. More information is available on the company website: https://www.rsipvision.com/.

About BioView Ltd
Established in 2000, and led by an expert team of biologists, software engineers, and physicists, BioView develops, manufactures, and supplies cell imaging equipment, and analysis software to medical institutes and universities. BioView is a publicly traded company on the Tel Aviv Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions. For more information about the BioView technology, and press related issues, please contact alan@bioview.co.il or visit our website at http://www.bioview.com.

SOURCE RSIP Vision